NASDAQ:SPRY

ARS Pharmaceuticals (SPRY) Stock Forecast, Price & News

$3.78

+0.13 (+3.56%)

(As of 09/29/2023 ET)

Compare

Today's Range: $3.63
▼
$3.86
50-Day Range: $2.92
▼
$7.48
52-Week Range: $2.55
▼
$9.65

Volume: 963,018 shs
Average Volume: 2.88 million shs
Market Capitalization: $361.25 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.00

ARS Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Hold
2.25 Rating Score
Upside/Downside: 217.5% Upside
$12.00 Price Target
Short Interest: Bearish
14.19% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.60
Based on 17 Articles This Week
Insider Trading: Acquiring Shares
$31.43 M Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.71) to ($0.87) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

667th out of 972 stocks

Pharmaceutical Preparations Industry

313th out of 449 stocks

3.1

Analyst's Opinion

Consensus Rating
ARS Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $12.00, ARS Pharmaceuticals has a forecasted upside of 217.5% from its current price of $3.78.
Amount of Analyst Coverage
ARS Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
14.19% of the float of ARS Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
ARS Pharmaceuticals has a short interest ratio ("days to cover") of 5.1.
Change versus previous month
Short interest in ARS Pharmaceuticals has recently increased by 7.64%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
ARS Pharmaceuticals does not currently pay a dividend.
Dividend Growth
ARS Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SPRY.

3.1

News and Social Media Coverage

News Sentiment
ARS Pharmaceuticals has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 17 news articles for ARS Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
23 people have searched for SPRY on MarketBeat in the last 30 days.
MarketBeat Follows
16 people have added ARS Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 433% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ARS Pharmaceuticals insiders have bought 1,924.78% more of their company's stock than they have sold. Specifically, they have bought $31,431,000.00 in company stock and sold $1,552,313.00 in company stock.
Percentage Held by Insiders
35.60% of the stock of ARS Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
57.41% of the stock of ARS Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for ARS Pharmaceuticals are expected to decrease in the coming year, from ($0.71) to ($0.87) per share.
Price to Book Value per Share Ratio
ARS Pharmaceuticals has a P/B Ratio of 1.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About ARS Pharmaceuticals (NASDAQ:SPRY) Stock

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for patients and parents affected by severe allergic reactions. It is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for patients and their caregivers with type I allergic reactions, including anaphylaxis. The company was founded in 2015 and is based in San Diego, California.

SPRY Price History

30 days | 90 days | 365 days | Advanced Chart

SPRY Stock News Headlines

September 29, 2023 | finance.yahoo.com

ARS Pharmaceuticals, Harmonic, and More Stocks See Action From Activist Investors

September 29, 2023 | finance.yahoo.com

3 Small Biotech Stocks That Could Be Stars

October 1, 2023 | Stansberry Research (Ad)

Experts: "NVIDIA Bubble" Could Affect Entire Market

Several major analysts are warning that NVIDIA and other tech giants may have gotten “too big to succeed”.

September 28, 2023 | finance.yahoo.com

We're Hopeful That ARS Pharmaceuticals (NASDAQ:SPRY) Will Use Its Cash Wisely

September 26, 2023 | benzinga.com

Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday

September 26, 2023 | benzinga.com

Director At This Health Care Company Buys $8.18M of Stock

September 26, 2023 | americanbankingnews.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Ra Capital Management, L.P. Buys 2,700,000 Shares of Stock

September 25, 2023 | americanbankingnews.com

Leerink Partnrs Comments on ARS Pharmaceuticals, Inc.'s FY2023 Earnings (NASDAQ:SPRY)

October 1, 2023 | Stansberry Research (Ad)

Experts: "NVIDIA Bubble" Could Affect Entire Market

Several major analysts are warning that NVIDIA and other tech giants may have gotten “too big to succeed”.

September 25, 2023 | americanbankingnews.com

FY2023 Earnings Estimate for ARS Pharmaceuticals, Inc. Issued By Wedbush (NASDAQ:SPRY)

September 23, 2023 | americanbankingnews.com

ARS Pharmaceuticals (NASDAQ:SPRY) Rating Lowered to Market Perform at SVB Leerink

September 23, 2023 | americanbankingnews.com

ARS Pharmaceuticals (NASDAQ:SPRY) Given New $5.00 Price Target at Wedbush

September 23, 2023 | americanbankingnews.com

Research Analysts Set Expectations for ARS Pharmaceuticals, Inc.'s Q3 2023 Earnings (NASDAQ:SPRY)

September 23, 2023 | americanbankingnews.com

ARS Pharmaceuticals (NASDAQ:SPRY) Rating Lowered to Market Perform at Leerink Partnrs

September 22, 2023 | msn.com

ARS Pharmaceuticals' EpiPen Alternative Delayed US Approval - Two Analysts Offer Differing Views

September 22, 2023 | americanbankingnews.com

ARS Pharmaceuticals (NASDAQ:SPRY) Rating Lowered to Market Perform at William Blair

September 21, 2023 | markets.businessinsider.com

What's Going On With ARS Pharmaceuticals Stock Today?

September 21, 2023 | finance.yahoo.com

ARS Pharmaceuticals (SPRY) Down on CRL for Nasal Spray

September 21, 2023 | msn.com

ARS Pharma (NASDAQ:SPRY) Plummets on FDA Snub for Epinephrine Nasal Spray

September 21, 2023 | finance.yahoo.com

Fed’s Message Is Louder Than Its Rate Call. Why That’s Critical for Investors.

September 20, 2023 | msn.com

FDA Declines to Approve Epinephrine Nasal-Spray, Asks for Additional Data

September 20, 2023 | msn.com

ARS Pharma shares plummet after FDA asks for extra test of nasal spray

September 20, 2023 | marketwatch.com

ARS Pharmaceuticals Shares Sink to New Lows on FDA Neffy Setback >SPRY

September 20, 2023 | msn.com

ARS Pharma hits 52-week low as William Blair downgrades on FDA snub

September 20, 2023 | msn.com

Biggest stock movers today: Instacart, ARS Pharmaceuticals and more

September 20, 2023 | marketwatch.com

ARS Pharmaceuticals Shares Sink Premarket as FDA Rejects Neffy Spray >SPRY

September 20, 2023 | markets.businessinsider.com

ARS Pharma : FDA Issues CRL For Nasal Spray NDA With Request For Addl Study; Stock Down

See More Headlines

Receive SPRY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ARS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SPRY Company Calendar

Last Earnings: 8/10/2023
Today: 10/01/2023
Next Earnings (Estimated): 11/01/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SPRY
CUSIP: N/A
CIK: 1671858
Web: ars-pharma.com
Phone: 206-456-2900
Fax: N/A
Employees: 29
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $12.00
High Stock Price Forecast: $17.00
Low Stock Price Forecast: $5.00
Forecasted Upside/Downside: +217.5%
Consensus Rating: Hold
Rating Score (0-4): 2.25
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-34,680,000.00
Net Margins: N/A
Pretax Margin: -24,357.53%
Return on Equity: -20.33%
Return on Assets: -19.71%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 25.37
Quick Ratio: 25.37

Sales & Book Value

Annual Sales: $219,000.00
Price / Sales: 1,649.53
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.90 per share
Price / Book: 1.30

Miscellaneous

Outstanding Shares: 95,568,000
Free Float: 61,546,000
Market Cap: $361.25 million
Optionable: Optionable
Beta: -0.12

10 Best Stocks to Own in 2023

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Richard Lowenthal M.B.A. (Age 57)
M.S., MSMSEL, Founder, Pres, CEO & Director
Comp: $908.83k

Dr. Sarina Tanimoto M.B.A. (Age 55)
M.D., Co-Founder & Chief Medical Officer
Comp: $748.97k

Mr. Eric Karas (Age 51)
Chief Commercial Officer
Comp: $618.61k

Dr. Robert Bell Ph.D.
Co-Founder & Chief Science Officer

Ms. Kathleen D. Scott CPA
Chief Financial Officer

Mr. Brian T. Dorsey M.S. (Age 55)
Chief Operations Officer

Mr. Alexander A. Fitzpatrick Esq. (Age 56)
Chief Legal Officer & Sec.

Mr. Daniel Relovsky
Sr. VP of Marketing

Mr. Harris Kaplan M.B.A. (Age 71)
MBA, Exec. VP of Commercial Strategy

Mr. Justin Chakma (Age 33)
Chief Bus. Officer & Sec.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SPRY Stock - Frequently Asked Questions

Should I buy or sell ARS Pharmaceuticals stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ARS Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" SPRY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SPRY, but not buy additional shares or sell existing shares.
View SPRY analyst ratings or view top-rated stocks.
What is ARS Pharmaceuticals' stock price forecast for 2023?: 4 Wall Street research analysts have issued 12 month price targets for ARS Pharmaceuticals' shares. Their SPRY share price forecasts range from $5.00 to $17.00. On average, they expect the company's stock price to reach $12.00 in the next year. This suggests a possible upside of 217.5% from the stock's current price.
View analysts price targets for SPRY or view top-rated stocks among Wall Street analysts.
How have SPRY shares performed in 2023?: ARS Pharmaceuticals' stock was trading at $8.53 on January 1st, 2023. Since then, SPRY shares have decreased by 55.7% and is now trading at $3.78.
View the best growth stocks for 2023 here.
When is ARS Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our SPRY earnings forecast.

How were ARS Pharmaceuticals' earnings last quarter?: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) issued its quarterly earnings results on Thursday, August, 10th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.17) by $0.01. The business earned $0.01 million during the quarter.
What is ARS Pharmaceuticals' stock symbol?: ARS Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPRY."
How do I buy shares of ARS Pharmaceuticals?: Shares of SPRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is ARS Pharmaceuticals' stock price today?: One share of SPRY stock can currently be purchased for approximately $3.78.
How much money does ARS Pharmaceuticals make?: ARS Pharmaceuticals (NASDAQ:SPRY) has a market capitalization of $361.25 million and generates $219,000.00 in revenue each year.
How can I contact ARS Pharmaceuticals?: ARS Pharmaceuticals' mailing address is 500 Fairview Ave N Suite 600, Seattle WA, 98109. The official website for the company is ars-pharma.com. The company can be reached via phone at 206-456-2900 or via email at ir@silverbacktx.com.

This page (NASDAQ:SPRY) was last updated on 10/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

ARS Pharmaceuticals (SPRY) Stock Forecast, Price & News

ARS Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About ARS Pharmaceuticals (NASDAQ:SPRY) Stock

SPRY Price History

SPRY Stock News Headlines

SPRY Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

SPRY Stock - Frequently Asked Questions

Overall MarketRank^™